In vitro assessment of farnesoid X receptor antagonism to predict drug-induced liver injury risk

被引:6
作者
Norona, Leah M. [1 ]
Fullerton, Aaron [1 ]
Lawson, Chris [1 ]
Leung, Leslie [1 ]
Brumm, Jochen [2 ]
Kiyota, Tomomi [1 ]
Maher, Jonathan [1 ]
Khojasteh, Cyrus [3 ]
Proctor, William R. [1 ]
机构
[1] Genentech Inc, Safety Assessment, Predict Toxicol, San Francisco, CA 94080 USA
[2] Genentech Inc, Nonclin Biostat, Prod Dev, San Francisco, CA 94080 USA
[3] Genentech Inc, Dept Drug Metab & Pharmacokinet, San Francisco, CA 94080 USA
关键词
DILI; BSEP; FXR antagonism; Hepatotoxicity; Cholestasis; SALT EXPORT PUMP; BILE-ACID; CYTOCHROME-P450; EXPRESSION; INHIBITION; IDENTIFICATION; TRANSPORTERS; DISPOSITION; MODULATORS; DISCOVERY; TOOL;
D O I
10.1007/s00204-020-02804-4
中图分类号
R99 [毒物学(毒理学)];
学科分类号
100405 ;
摘要
Drug-induced liver injury (DILI) continues to be a major cause of drug attrition and restrictive labeling. Given the importance of farnesoid X receptor (FXR) in bile acid homeostasis, drug-related FXR antagonism may be an important mechanism of DILI. However, a comprehensive assessment of this phenomenon broadly in the context of DILI is lacking. As such, we used an orthogonal approach comprising a FXR target gene assay in primary human hepatocytes and a commercially available FXR reporter assay to investigate the potential FXR antagonistic effects of an extensive test set of 159 compounds with and without association with clinical DILI. Data were omitted from analysis based on the presence of cytotoxicity to minimize false positive assay signals and other complications in data interpretation. Based on the experimental approaches employed and corresponding data, the prevalence of FXR antagonism was relatively low across this broad DILI test set, with 16-24% prevalence based on individual assay results or combined signals in both assays. Moreover, FXR antagonism was not highly predictive for identifying clinically relevant hepatotoxicants retrospectively, where FXR antagonist classification alone had minimal to moderate predictive value as represented by positive and negative likelihood ratios of 2.24-3.84 and 0.72-0.85, respectively. The predictivity did not increase significantly when considering only compounds with high clinical exposure (maximal or efficacious plasma exposures > 1.0 mu M). In contrast, modest gains in predictive value of FXR antagonism were observed considering compounds that also inhibit bile salt export pump. In addition, we have identified novel FXR antagonistic effects of well-studied hepatotoxic drugs, including bosentan, tolcapone and ritonavir. In conclusion, this work represents a comprehensive evaluation of FXR antagonism in the context of DILI, including its overall predictivity and challenges associated with detecting this phenomenon in vitro.
引用
收藏
页码:3185 / 3200
页数:16
相关论文
共 58 条
  • [1] Moving beyond Binary Predictions of Human Drug-Induced Liver Injury (DILI) toward Contrasting Relative Risk Potential
    Aleo, Michael D.
    Shah, Falgun
    Allen, Scott
    Barton, Hugh A.
    Costales, Chester
    Lazzaro, Sarah
    Leung, Louis
    Nilson, Andrea
    Obach, R. Scott
    Rodrigues, A. David
    Will, Yvonne
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2020, 33 (01) : 223 - 238
  • [2] Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals
    Aleo, Michael D.
    Shah, Falgun
    He, Kan
    Bonin, Paul D.
    Rodrigues, A. David
    [J]. CHEMICAL RESEARCH IN TOXICOLOGY, 2017, 30 (05) : 1219 - 1229
  • [3] Human Drug-Induced Liver Injury Severity Is Highly Associated With Dual Inhibition of Liver Mitochondrial Function and Bile Salt Export Pump
    Aleo, Michael D.
    Luo, Yi
    Swiss, Rachel
    Bonin, Paul D.
    Potter, David M.
    Will, Yvonne
    [J]. HEPATOLOGY, 2014, 60 (03) : 1015 - 1022
  • [4] DIAGNOSTIC-TESTS-2 - PREDICTIVE VALUES .4.
    ALTMAN, DG
    BLAND, JM
    [J]. BRITISH MEDICAL JOURNAL, 1994, 309 (6947) : 102 - 102
  • [5] Stable Expression, Activity, and Inducibility of Cytochromes P450 in Differentiated HepaRG Cells
    Antherieu, Sebastien
    Chesne, Christophe
    Li, Ruoya
    Camus, Sandrine
    Lahoz, Agustin
    Picazo, Laura
    Turpeinen, Miia
    Tolonen, Ari
    Uusitalo, Jouko
    Guguen-Guillouzo, Christiane
    Guillouzo, Andre
    [J]. DRUG METABOLISM AND DISPOSITION, 2010, 38 (03) : 516 - 525
  • [6] FXR: Big fish or small fry for drug-induced liver injury?
    Ballet, Francois
    [J]. CLINICS AND RESEARCH IN HEPATOLOGY AND GASTROENTEROLOGY, 2016, 40 (01) : 6 - 8
  • [7] Benabou Reina, 2003, Expert Opin Drug Saf, V2, P263, DOI 10.1517/eods.2.3.263.21375
  • [8] Measures of BSEP Inhibition In Vitro Are Not Useful Predictors of DILI
    Chan, Rosa
    Benet, Leslie Z.
    [J]. TOXICOLOGICAL SCIENCES, 2018, 162 (02) : 499 - 508
  • [9] DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans
    Chen, Minjun
    Suzuki, Ayako
    Thakkar, Shraddha
    Yu, Ke
    Hu, Chuchu
    Tong, Weida
    [J]. DRUG DISCOVERY TODAY, 2016, 21 (04) : 648 - 653
  • [10] High Lipophilicity and High Daily Dose of Oral Medications Are Associated With Significant Risk for Drug-Induced Liver Injury
    Chen, Minjun
    Borlak, Juergen
    Tong, Weida
    [J]. HEPATOLOGY, 2013, 58 (01) : 388 - 396